If the news that UK interventional medicine specialist BTG PLC, strong, independent and fiercely committed to immovable quality standards in terms of its own M&A programs, is to be acquired was unexpected by many, the identity of the buyer was less of a surprise: Boston Scientific Corp. proved on Nov. 20 that its appetite for major M&A in 2018 is not yet exhausted when it made a bid for BTG, valuing the company at £3.3 billion ($4.28 billion).
In Vivo has tracked BTG of late, charting its ability to precision-target commercial entities that fit its interventional oncology and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?